Skip to main content

ATMP Engage

About ATMP Engage

The Advanced Therapy Medicinal Products Patient and Public Involvement and Engagement Working Group (ATMP Engage) brings together UK-based stakeholders with an interest in ATMPs to discuss and collaborate on PPIE activity.

Overarching aims

  • to ensure patients are at the heart of ATMP research and implementation developments
  • to raise the public and patient profile of ATMPs
  • to uphold and share best practice on PPIE with respect to ATMPs


Communication ATMP Engage working groups

ATMP Engage has created several working sub-groups, each focusing on different priority areas within PPIE around ATMPs.

PPI Directory Resources for developers of cell and gene therapies

The ATMP Engage PPI Directory contains patient and public involvement (PPI) resources for developers of cell and gene therapies, including toolkits, guidelines, advice, templates and case studies.

Online information Resources for patients and other public stakeholders

ATMP Engage has collated online information provided by or recommended by our members about cell and gene therapies, including advanced therapy medicinal products (ATMPs).

Patient Story Charlie and Rupert: Spinal Muscular Atrophy and Zolgensma

Rupert was diagnosed with Spinal Muscular Atrophy type 1 when he was 8 weeks old. He received the gene therapy Zolgensma, an advanced therapy medicinal product (ATMP), at 11 weeks old.

Workshop Report Providing good information to involve and engage

Genetic Alliance UK and EuroGCT joined forces to progress our understanding of the information needs of people living with rare conditions who wish to engage with gene and cell therapy progress.

Report ATMPs and Equity of Access

On behalf of the ATMP Engage Equity of Access working subgroups, Genetic Alliance UK produced a report on equity of access to advanced therapies within the UK.

Online information ATMP Engage: PPIE Resources

Resources for researchers, patients, and communicators, collated by the ATMP Engage partners.

Working Group Membership

The membership includes patient partners with lived or relevant experience, and representatives from charities, research, industry and health system organisations. It was co-chaired in 2021-2022 by Genetic Alliance UK and NHS England and Improvement as a key workstream of the Accelerated Access Collaborative's work to support ATMPs. In 2022-2023 the working group is co-chaired by Genetic Alliance UK and the Advanced Therapy Treatment Centres, coordinated by the Cell and Gene Therapy Catapult.

List of members and Terms of Reference

If you are interested in getting involved, submit a collaboration enquiry via the EuroGCT contact form.